ESR1 and breast cancer: As mentioned, the therapeutic options currently at the disposal of BC oncologists have undeniably resulted in survival benefits for patients bearing tumors of the estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (Her2)-positive subtypes, respectively.